No Data
No Data
Amedisys Is Maintained at Market Perform by Raymond James
Amedisys Is Maintained at Market Perform by Raymond James
Raymond James Maintains Market Perform on Amedisysto Market Perform
Raymond James analyst John Ransom maintains Amedisys from Market Perform to Market Perform.
Amedisys Acquisition by UnitedHealth Unit Seen to Close Despite Potential DOJ Probe, RBC Says
Amedisys' (AMED) acquisition by UnitedHealth Group's (UNH) Optum unit is expected to be completed despite unconfirmed reports of a possible antitrust investigation by the US Department of Justice, RBC Capital Markets said in a note Monday.
Why Amedisys (AMED) Is a Top Value Stock for the Long-Term
Amedisys Is Maintained at Outperform by RBC Capital
Amedisys Is Maintained at Outperform by RBC Capital
Amedisys Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/25/2024 8.52% RBC Capital $97 → $100 Maintains Outperform 09/14/2023 9.6% Cantor Fitzgerald $100 → $101
No Data